FLT3 and acute myeloid leukemia: Stratification of NK-AML patients according to FLT3 or NPM1 status, revealed a significantly reduced OS for NK-AML rs2853669 CC genotypes among FLT3-ITD or NPM1 non-mutated patients (4.6 months compared to 11.8 or 12.6 months ( p < 0.001) for the TC or TT genotypes, respectively (Figure 2C).